Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have earned an average rating of “Hold” from the eleven research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $13.28.
Several research firms recently commented on AMAG. ValuEngine lowered AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 3rd. BidaskClub upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 23rd. Barclays reiterated a “buy” rating and issued a $14.00 price target (down previously from $16.00) on shares of AMAG Pharmaceuticals in a research report on Sunday, November 3rd. Needham & Company LLC reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Friday, October 25th. Finally, Piper Jaffray Companies lowered AMAG Pharmaceuticals from a “neutral” rating to an “underweight” rating and dropped their price target for the stock from $9.00 to $6.00 in a research report on Wednesday, October 30th.
Several large investors have recently made changes to their positions in the business. Tyers Asset Management LLC boosted its position in shares of AMAG Pharmaceuticals by 32.2% during the second quarter. Tyers Asset Management LLC now owns 5,840 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 1,424 shares during the period. Swiss National Bank boosted its position in shares of AMAG Pharmaceuticals by 2.4% during the second quarter. Swiss National Bank now owns 64,457 shares of the specialty pharmaceutical company’s stock valued at $644,000 after buying an additional 1,500 shares during the period. Riverhead Capital Management LLC boosted its position in shares of AMAG Pharmaceuticals by 30.1% during the second quarter. Riverhead Capital Management LLC now owns 6,483 shares of the specialty pharmaceutical company’s stock valued at $65,000 after buying an additional 1,500 shares during the period. Elkfork Partners LLC boosted its position in shares of AMAG Pharmaceuticals by 32.2% during the second quarter. Elkfork Partners LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $80,000 after buying an additional 1,958 shares during the period. Finally, Bank of Montreal Can boosted its position in shares of AMAG Pharmaceuticals by 211.9% during the second quarter. Bank of Montreal Can now owns 3,209 shares of the specialty pharmaceutical company’s stock valued at $32,000 after buying an additional 2,180 shares during the period.
Shares of AMAG Pharmaceuticals stock traded up $0.02 during trading on Friday, reaching $12.19. 206,162 shares of the stock traded hands, compared to its average volume of 472,213. The company has a market capitalization of $411.67 million, a price-to-earnings ratio of -3.14 and a beta of 0.35. The business has a fifty day simple moving average of $11.10 and a two-hundred day simple moving average of $10.61. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.67 and a quick ratio of 1.53. AMAG Pharmaceuticals has a 52-week low of $6.81 and a 52-week high of $17.39.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Friday, November 1st. The specialty pharmaceutical company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.19). The firm had revenue of $84.13 million for the quarter, compared to analysts’ expectations of $88.25 million. AMAG Pharmaceuticals had a negative net margin of 88.54% and a negative return on equity of 34.59%. The company’s revenue for the quarter was down 31.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.89 EPS. On average, research analysts predict that AMAG Pharmaceuticals will post -3.83 earnings per share for the current fiscal year.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Further Reading: Differences Between Momentum Investing and Long Term Investing
-